Airing weekdays at 7:30 A.M. on

Airing weekdays at 7:30 A.M. on
Share

The EB Research Partnership is the largest global organization dedicated to funding research to treat and cure Epidermolysis Bullosa or EB. Their goal? To cure EB by 2030 with the Venture Into Cures methodology, which is changing the model for rare disease research funding.

We’re joined by Michael Hund, CEO of the EB Research Partnership, and Alexander Gambon, Chief Brand Officer at Elongate, who together are bridging the gap between cryptocurrency and charity. We’ll also sit down with Chris and Eileen Attar, whose 5-year-old son Brady has EB, to see how this disease affects their family and how they are determined to have their son live a full life, despite his rare disease.

Credits: Ian Jones & Wikimedia Commons

  Kate Middleton has announced to the world that she has cancer. The Princess of Wales revealed she is undergoing chemotherapy in a personal video message shared on March 22. The news came after weeks of speculation on the Princess of Wales’s health following her “planned abdominal surgery” in January. Personal Video Message “In January, I underwent […]

Share

Making big strides in the treatment of small cell lung cancer. Plus, how to manage your diabetes with confidence.

Share

Small cell lung cancer (SCLC) stands as a formidable adversary in the realm of oncology, representing a highly aggressive form of lung cancer notorious for its rapid growth and propensity to metastasize early.

Share

Comments

comments